Salem Radio Network News Wednesday, November 18, 2026

Health

British cancer drug developer Ellipses Pharma considers London listing

Carbonatix Pre-Player Loader

Audio By Carbonatix

(Corrects typographical error in headline)

Nov 18 (Reuters) – British cancer drug developer Ellipses Pharma on Wednesday said it was exploring a London listing through a deal with  special purpose acquisition company Wolfram Resources. 

• Established in 2017, Ellipses Pharma’s pipeline includes trials for drugs to treat non-small cell lung cancer and breast cancer

• The company plans to list its shares on the London bourse following a reverse takeover by shell company Wolfram Resources, whose terms are yet to be agreed

• The floatation will provide a much-needed boost to the UK’s market which has seen an exodus from companies eyeing higher valuations in markets like the United States

• Ellipses Pharma said it is targeting completing the transaction by early 2027

• The firm also expects an equity fundraise in conjunction with the deal

• Listing through a reverse takeover process will enable the company to raise additional capital from public company investors, founder and chair Chris Evans said

(Reporting by Simone Lobo in Bengaluru; Editing by Nivedita Bhattacharjee)

Previous
Next
The Media Line News
X CLOSE